美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.36

+0.10590.31%

盤後：34.35-0.0059-0.02%19:59 EDT

成交量：1.97萬

成交額：67.75萬

市值：9,550.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.95

換手率：0.71%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

石藥集團：SYH2085片II期臨床試驗在中國正式啓動

繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗

恒瑞醫藥(01276)：SHR-1179注射液獲得藥物臨床試驗批准通知書

榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

諾和諾德再次暫停了其實驗性心臟病藥物的兩項臨床試驗，進一步打擊了該藥的發展前景。

艾迪藥業：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

恒瑞醫藥(600276.SH)子公司HRS-1597片獲批開展臨床試驗

智飛生物(300122.SZ)：重組輪狀病毒亞單位疫苗(大腸桿菌)獲得臨床試驗批准

恒瑞醫藥：子公司HRS-1597片獲臨床試驗批准

恒瑞醫藥：HRS-6209膠囊、HRS-4508片獲臨床試驗批准

南方财经网

華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批目前國內尚無流感病毒mRNA疫苗產品獲批上市

華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批目前國內尚無流感病毒mRNA疫苗產品獲批上市

智飛生物：重組輪狀病毒亞單位疫苗獲臨床試驗批准

華蘭疫苗：新型流感病毒mRNA疫苗獲臨床試驗批准

諾華降膽固醇藥物遭遇挫折，令人們對新興心臟病藥物的期望蒙上陰影

轉型陣痛的昂利康：傳統業務增長失速，豪賭創新藥前景未明

甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥

一周兩度受挫！諾華(NVS.US)心臟病重磅藥III期折戟，股價大跌安進(AMGN.US)「躺槍」

我國首款AI輔助創新藥獲批上市，機構扎堆關注12只概念股

創新藥概念震盪反彈德展健康3天2板

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19691,"hourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"已收盤","change":0.1059,"latestTime":"09-16 16:00:00 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":677542.144902,"amplitude":0.012286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.27126,"aum":95274137.07126,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"volumeRatio":0.950696,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.950696,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"eps":0,"divideRate":0.007478,"volume":19691,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665319936","title":"石藥集團：SYH2085片II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319936","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319936?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:28","pubTimestamp":1788780492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","BMED","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831989","title":"繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831989?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:10","pubTimestamp":1788779458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","IE0009355771.USD","IE00B4R5TH58.HKD","BMED","BK4532","IE00BJJMRZ35.SGD","NVS","LU0211331839.USD","MEDX","IE0002141913.USD","BGIA","IE00BJT1NW94.SGD","IBBJ","BK4578","PSYK","BK4588","LU0320765489.SGD","MDTX","BK4007","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4585","IBBQ","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665031616","title":"恒瑞醫藥(01276)：SHR-1179注射液獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2665031616","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665031616?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:49","pubTimestamp":1788778166,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 SHR-1179 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1179 注射液是公司自主研发的治疗用 1 类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179 注射液相关项目累计研发投入约2,420万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","MDTX","LU1328615791.USD","LU2289578879.USD","BK0012","BMED","BK0060","LU2580892862.HKD","LU2580892789.USD","IBBQ","LU0359201885.HKD","LU0359201612.USD","LU2097828714.EUR","LU1064131003.USD","LU1255011170.USD","LU1781817850.SGD","BK0188","LU1064130708.USD","LU1146622755.USD","LU1580142542.USD","LU2543165471.USD","BK0028","LU1969619763.USD","600276","01276","BK0196","LU1655091616.SGD","LU0359202008.SGD","LU2097828631.EUR","PSYK","BK0183","LU1997245177.USD","LU2097828557.USD","LU2488822045.USD","LU1023057109.AUD","LU2097828474.EUR","LU2495084118.USD","BK0239","IBBJ","BK1191","LU1997245094.SGD","LU0405327148.USD","LU1820825898.SGD","LU2328871848.SGD","LU1997244956.HKD","LU2097828805.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731933","title":"榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731933","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665731933?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，荣昌生物发布公告称，公司计划于2026年9月16日15：00-17：00参加2026年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09995","LU2328871848.SGD","BK1583","LU2148510915.USD","LU1969619763.USD","IBBQ","LNGR","MEDX","BK0239","06978","LU1064130708.USD","LU2488822045.USD","BK1574","BK1161","688331","159992","KSTR","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315689","title":"諾和諾德再次暫停了其實驗性心臟病藥物的兩項臨床試驗，進一步打擊了該藥的發展前景。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:02","pubTimestamp":1788775332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","BGIA","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319730","title":"艾迪藥業：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319730","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319730?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:01","pubTimestamp":1788775260,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，艾迪药业发布公告称，公司计划于2026年9月16日15：00-17：00参与由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0262","LNGR","BK1574","IBBQ","159992","BK1161","06978","MEDX","KSTR","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313519","title":"恒瑞醫藥(600276.SH)子公司HRS-1597片獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665313519?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 17:18","pubTimestamp":1788772689,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1597片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1597片是公司自主研发的1类新药，拟用于体重管理。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1597片相关项目累计研发投入约1690万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU1997244956.HKD","BMED","BK1191","LU1146622755.USD","LU2097828474.EUR","LU2495084118.USD","LU1064130708.USD","LU2097828714.EUR","BK0012","LU0405327494.USD","LU1064131003.USD","LU2328871848.SGD","LU2148510915.USD","LU2488822045.USD","LU1655091616.SGD","LU2097828631.EUR","BK0060","LU0405327148.USD","LU1781817850.SGD","LU2289578879.USD","LU1023057109.AUD","BK0196","LU2580892789.USD","IBBQ","LU2097828557.USD","PSYK","LU1997245094.SGD","LU1997245177.USD","IBBJ","01276","LU0359202008.SGD","LU2543165471.USD","LU1820825898.SGD","LU1328615791.USD","600276","BK0239","MDTX","LU2580892862.HKD","LU1580142542.USD","BK0028","LU2097828805.USD","LU1969619763.USD","BK0183","LU0359201885.HKD","LU1255011170.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313385","title":"智飛生物(300122.SZ)：重組輪狀病毒亞單位疫苗(大腸桿菌)獲得臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665313385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 17:15","pubTimestamp":1788772542,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司北京智飞绿竹生物制药有限公司研发的重组轮状病毒亚单位疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展预防轮状病毒感染引起的急性胃肠炎的临床试验。公司的重组轮状病毒亚单位疫苗采用重组大肠杆菌发酵、纯化等工艺，获得三种基因型的重组VP8蛋白，经佐剂吸附制备成疫苗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1064130708.USD","BK0077","BK0196","BMED","LU1064131003.USD","BK0046","LU2580892789.USD","300122","IBBQ","BK0188","MDTX","159646","PSYK","BK0239","IBBJ","LU2580892862.HKD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831854","title":"恒瑞醫藥：子公司HRS-1597片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:47","pubTimestamp":1788770825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBJ","BMED","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665181063","title":"恒瑞醫藥：HRS-6209膠囊、HRS-4508片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665181063","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665181063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:47","pubTimestamp":1788770820,"startTime":"0","endTime":"0","summary":"南财智讯9月7日电，恒瑞医药公告，HRS-6209胶囊、HRS-4508片收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展临床试验。通知书明确：HRS-6209联合其他抗肿瘤治疗在晚期不可切除或转移性乳腺癌，或HRS-9813在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效的开放、多中心Ib/II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866721614.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866721614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","01276","LU1064130708.USD","BMED","LU1328615791.USD","LU1023057109.AUD","IBBQ","BK0012","LU2328871848.SGD","LU0405327494.USD","LU2148510915.USD","BK1191","LU1997245094.SGD","LU1997245177.USD","LU2097828631.EUR","600276","LU1255011170.USD","LU2097828474.EUR","LU2580892862.HKD","BK0183","LU2488822045.USD","LU0359201612.USD","LU2495084118.USD","LU1655091616.SGD","PSYK","LU2097828557.USD","LU1146622755.USD","LU2580892789.USD","MDTX","LU1781817850.SGD","LU1997244956.HKD","LU1820825898.SGD","LU1064131003.USD","LU1969619763.USD","LU2097828805.USD","LU0359201885.HKD","BK0239","LU0359202008.SGD","IBBJ","BK0060","BK0188","LU1580142542.USD","BK0028","LU2097828714.EUR","LU2543165471.USD","LU2289578879.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665550318","title":"華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批 目前國內尚無流感病毒mRNA疫苗產品獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665550318","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665550318?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:42","pubTimestamp":1788770526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华兰疫苗 发布公告，公司于近日收到国家药品监督管理局核准签发的关于新型流感病毒mRNA疫苗的《药物临床试验批准通知书》。公司研发的新型流感病毒mRNA疫苗采用mRNA技术路线，通过递送编码流感病毒相关抗原的mRNA，在体内表达相应抗原并诱导机体产生免疫应答。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","MRNX","MRNY","IBBJ","IPOS","BMED","301207","BK0239","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318561","title":"華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批 目前國內尚無流感病毒mRNA疫苗產品獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665318561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:42","pubTimestamp":1788770526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","IBBQ","MRNX","BMED","IBBJ","MDTX","PSYK","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665188143","title":"智飛生物：重組輪狀病毒亞單位疫苗獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665188143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665188143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:38","pubTimestamp":1788770300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BMED","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390071","title":"華蘭疫苗：新型流感病毒mRNA疫苗獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:37","pubTimestamp":1788770253,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","MRNY","IBBJ","MRNX","PSYK","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665699390","title":"諾華降膽固醇藥物遭遇挫折，令人們對新興心臟病藥物的期望蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665699390","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665699390?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:11","pubTimestamp":1788768711,"startTime":"0","endTime":"0","summary":"罕见病药物备受期待市场关注点现将转向第四季度其RNA疗法del-desiran的后期临床试验结果。该药物用于治疗一种罕见肌肉疾病，系通过收购Avidity公司获得。诺华公司另一款抗炎药物雷米布替尼针对一种名为脓疱性汗腺炎的皮肤病所开展的研究数据，预计也将于今年公布。该药物上周在多发性硬化症患者的临床试验中取得了成功。这两家竞争对手的药物均在与佩拉卡森类似的临床试验中进行测试，这些试验依赖于确诊的心脏相关事件，且没有明确的结束日期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nL4T44Z0IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IXJ","LLY","LLII","JDOC","FHLC","CANC","PJP","IBB","LU2324357040.USD","IYH","NAMS","PPH","CURE","ELIL","LU0456855351.SGD","GDOC","TMED","IE00BK4W5L77.USD","LU1988902786.USD","VHT","PBE","FTXH","LU2491049909.HKD","BIB","IHE","ELIS","LLYZ","TBXU","ILDR","SLN","AGNG","LU1551013425.SGD","LU2746668974.SGD","AMGN","THNR","LU0096364046.USD","IBBQ","BBH","BK4588","MHIP","XLV","MEDX","MEDI","TRUH","WDNA","BK4581","RXL","OZEM","HRTS","LLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665904373","title":"轉型陣痛的昂利康：傳統業務增長失速，豪賭創新藥前景未明","url":"https://stock-news.laohu8.com/highlight/detail?id=2665904373","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665904373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:08","pubTimestamp":1788768480,"startTime":"0","endTime":"0","summary":"证券之星注意到，2026年上半年，昂利康营收、净利双双下滑逾10%，传统业务中原料药收入持续缩水，特色中间体规模更是“腰斩”，成为主要拖累。传统业务增长失速、创新业务远水难解，昂利康能否在多重压力中突围，仍有待时间检验。昂利康提示风险称，肿瘤创新药产品各阶段的成功率相对于其他创新药低，风险较高，不确定性较大。昂利康如何在传统业务与创新药漫长培育期之间找到平衡，才是市场关注的焦点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-07/doc-iniqyvry5536300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","LNGR","BK0239","159992","06978","BK1161","IBBQ","MEDX","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397088","title":"甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665397088?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:52","pubTimestamp":1788767548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，公司全资子公司甘李药业山东有限公司自主研发的GZC8072片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GZC8072片是新一代偏向型超长效多肽口服周制剂，正在开展用于肥胖或超重、2型糖尿病的适应症的临床试验。据悉，该产品于2026年8月、9月分别获得国家药品监督管理局下发的适应症为肥胖或超重、2型糖尿病的《药品临床试验批准通知书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","PSYK","IBBQ","BK0239","BMED","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392789","title":"一周兩度受挫！諾華(NVS.US)心臟病重磅藥III期折戟，股價大跌安進(AMGN.US)「躺槍」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392789?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:15","pubTimestamp":1788765302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药巨头诺华制药再遭临床试验打击——一周之内，该公司第二项重磅候选药物在后期研究中折戟。此次失利的是其潜在明星心脏病药物pelacarsen。受此消息影响，诺华在美上市股票上周五常规交易结束后一度下跌逾7%。开发类似心脏药物的安进股价上周五盘后也下挫近6%。诺华正寄望于一系列新药来支撑增长，以应对旗下多款重磅产品专利即将到期的压力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1057294990.SGD","IBBQ","BK4533","LU2242652126.USD","IE0009355771.USD","BK4007","LU2468319806.SGD","LU0320765992.SGD","NVS","BK4581","LU0070302665.USD","BK4139","LU0211331839.USD","PPH","IE00B2B36J28.USD","MEDX","BK4532","IE00BJT1NW94.SGD","LU2089984988.USD","IE0002141913.USD","LU2112291526.USD","BK4534","LU1571399168.USD","IBB","BK4599","BK4566","IE00BJJMRZ35.SGD","BBH","LU1061106388.HKD","BK4578","LU1023059063.AUD","SG9999001440.SGD","BIB","PBE","AMGN","LU0868494617.USD","IE00B4R5TH58.HKD","BK4588","LU0208291251.USD","IE00BFTCPJ56.SGD","TBXU","LU0109394709.USD","LU0320765489.SGD","LU0122379950.USD","PJP","LU2242646821.SGD","LU0889565916.HKD","LU0289739699.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665628399","title":"我國首款AI輔助創新藥獲批上市，機構扎堆關注12只概念股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665628399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665628399?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:35","pubTimestamp":1788755705,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","VTHR","AIPO","IBBQ","CHAT","IPOS","QTOC","MEDX","LNGR","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665895395","title":"創新藥概念震盪反彈 德展健康3天2板","url":"https://stock-news.laohu8.com/highlight/detail?id=2665895395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665895395?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:15","pubTimestamp":1788747304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":9,"totalSize":219,"code":"91000000","status":"200"}]}}